



Visegrad research meeting Under the auspices of Czech Myeloma Group

Chairmans: R. Hájek,

Visegrad research meeting is project of Czech Myeloma Group. It provides a platform for international communication in the management of patients with monoclonal gammopathies. This year, in 2021, is meeting focused on the update of research and clinical activities of cell therapy. New topic as reflection of „covid era“ will be analysis related to covid infection in haematological malignancies.

17:30 - 20:00 Roundtable – focus on collaborative research (virtual dinner during roundtable)

Thursday 18.03.2021

17:30 - 17:35 Roman Hájek (Ostrava)
Welcome reception/dinner

PART I: Covid era vs hematological malignancies

17:35 - 17:55 Dominik Dytfeld (Poznan)
Update on studies of Polish Myeloma Consortium
Analysis of Outcome of Covid Infection in Patients with Multiple Myeloma

17:55 - 18:05 Ondřej Šušol (Ostrava)
Covid Infection – Single Centre Experience

18:05 - 18:15 Artur Jurczynszyn (Krakow)
POEMS syndrome: real world experience in diagnosis and systemic therapy - 108 patients multicenter analysis

18:15 - 18:25 Varga Gergely (Budapest)
Venetoclax in Multiple Myeloma

Coffee break

PART II: Cell therapy projects and trials

18:30 - 18:45 Julio Rodriguez Bago (Ostrava)
Current status of preclinical and clinical research in cell-based therapy in Ostrava

18:45 - 19:00 Michal Šimíček (Ostrava)
Development of allogeneic CAR-T cells

19:00 - 19:15 Michal Šmída (Brno)
Identification of biomarkers and escape mechanisms for CAR-T cell therapy in chronic lymphocytic leukemia

19:15 - 19:30 Current status of CAR -T cell therapy in Visegrad countries (*all participants*)

19:45 + Possibility of collaborative research in cell therapy (*all participants*)